HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%

Phase 1Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Genital Herpes

Conditions

Genital Herpes

Trial Timeline

Feb 18, 2020 โ†’ May 19, 2021

About HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%

HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9% is a phase 1 stage product being developed by Merck for Genital Herpes. The current trial status is terminated. This product is registered under clinical trial identifier NCT04222985. Target conditions include Genital Herpes.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04222985Phase 1Terminated

Competing Products

20 competing products in Genital Herpes

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
15
Tideglusib + PlaceboAMO PharmaPhase 2/3
57
TideglusibAMO PharmaPhase 2/3
57
Fulvestrant + AbemaciclibEli LillyPhase 2
52
EDIT-101Editas MedicinePhase 1/2
33
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
77
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
ASP2151 + PlaceboAstellas PharmaPhase 1
33
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Topical NO + PlaceboKyowa KirinPhase 2
52
KW-3357Kyowa KirinPhase 1
33
Ixekizumab + PlaceboEli LillyPhase 3
77
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
77
DaratumumabJohnson & JohnsonPhase 2
52
Risankizumab + Placebo for RisankizumabAbbVieApproved
85